Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part IV

Speciality: Oncology


Speaker:

Dr. Todd Bauer | Senior Investigator, Sarah Cannon Research Institute, Medical Oncologist & Partner, Tennessee Oncology, PLLC Nashville

Dr. Ullas Batra | Co-Director, Dept of Medical Oncology Rajiv Gandhi Cancer Institute and Research Centre New Delhi

Dr. Bhupesh Gulleria | Medical Oncologist, Command Hospital, Pune

Dr. Deepak Gupta | Sr. Consultant Medical Oncology, BMCHRC. Jaipur

Dr. Nilesh Lokeshwar | Sr. Consultant Medical Oncology Kashyap Oncology Clinic, Mumbai

Description:

A warm welcome to all the medical professionals in this interesting learning session on understanding the best treatment approaches of ALK positive lung cancer.

In this webinar, a panel discussion would take place involving Dr. Todd Bauer as the primary speaker and Dr. Ullas Batra as a moderator who will share the important facts associated with treatment approaches for management of ALK positive lung cancer.

Dr. Todd Bauer has explained all details associated with the incidence, progression and treatment of ALK positive lung cancer. Further, a discussion on all possible treatment approaches and their pros, cons are discussed.

ALK-positive lung cancer represents about 4% of lung cancer which generally appears in adenocarcinoma non-small cell lung cancer. Patients with ALK-positive are mostly younger than the average lung cancer patient and also do not have a smoking history compared to other lung cancers.

Therefore,  you are going to have an overall knowledge regarding management of ALK positive lung cancer. Listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.


See More Webinars @ Hidoc Webinars




Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Weight loss trial reports success for breast cancer patients at one year mark

2.

Patients value communication skills from cancer surgeons across six key areas, according to research

3.

First-Line HCC Trial's Lenvatinib-Pembrolizumab Combo Misses Target.

4.

Reversing the toxic relationship with high doses of chemotherapy in oncology.

5.

Glioblastoma cells can 'unstick' from their neighbors to become more deadly


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot